**CLAIMS**

1. A pharmaceutical composition for nasal administration comprising (a) an effective amount of an active ester derivative of testosterone or a mixture of active ester derivatives of testosterone, and (b) a pharmaceutically acceptable oily vehicle.

2. A pharmaceutical composition according to Claim 1, in which the pharmaceutically acceptable oily vehicle is selected from any one or mixture of a vegetable oil and sucrose acetate isobutyrate (SAIB).

3. A pharmaceutical composition according to Claim 1 or 2, in which the pharmaceutically acceptable oily vehicle is a vegetable oil or mixture of vegetable oils.

4. A pharmaceutical composition according to Claim 1, 2 or 3, in which the pharmaceutically acceptable oily vehicle is comprised of >75% castor oil.

5. A pharmaceutical composition according to any preceding claim, in which the pharmaceutically acceptable oily vehicle is comprised of >75% medium chain triglycerides (MCT).

6. A pharmaceutical composition according to Claim 1 or 2, in which the pharmaceutically acceptable oily vehicle is sucrose acetate isobutyrate (SAIB).

7. A pharmaceutical composition according to any preceding claim, in which the active ester derivative of testosterone comprises about 1% to about 75% by weight of the pharmaceutical composition.

8. A pharmaceutical composition according to any preceding claim, which further comprises a wetting agent, a thickener, or water or any mixtures thereof, preferably which further comprises a thickener, more preferably which further comprises water.

9. A pharmaceutical composition according to any preceding claim, which is thixotropic.

10. A pharmaceutical composition according to any preceding claim, which is a solid or wax.

11. A pharmaceutical composition according to any preceding claim, in which the composition is placed in a spray dispenser for administration to a subject in need thereof.

12. A pharmaceutical composition according to any of Claims 1 to 10, in which the pharmaceutical composition is a gel for administration to a subject in need thereof.

13. A pharmaceutical composition according to any preceding claim, in which a single dose of said pharmaceutical composition delivers up to about 100 mg of testosterone per day.

14. A pharmaceutical composition according to any preceding claim, which allows a patient to self-medicate.

15. A pharmaceutical composition according to any preceding claim for use in a method of treatment of an indication from which a subject suffers, in which the pharmaceutical composition allows a patient to achieve in a single daily administration to both nostrils a quantity of testosterone sufficient to treat the indication.

16. A pharmaceutical composition according to any of Claims 1 to 13 for use in testosterone replacement therapy.

17. A pharmaceutical composition for use according to Claim 15 or 16, which comprises an effective mount of an active ester derivative of testosterone for achieving supraphysiological levels of testosterone for use to treat conditions selected from a group consisting of hypogonadism, anxiety, fear, sexual dysfunction, cancer, declining sexual drive, libido, testosterone replacement therapy, low testosterone, depression, anemia, prostate cancer and breast cancer.

**CLAIMS**

1. A pharmaceutical composition for nasal administration consisting of (a) an effective amount of an active ester derivative of testosterone or a mixture of active ester derivatives of testosterone, (b) a pharmaceutically acceptable oily vehicle; (c) a wetting agent or mixture of wetting agents and/or a pharmaceutically acceptable surfactant or mixture of surfactants; and optionally (d) a thickening agent; in which the active ester derivative of testosterone or mixture of active ester derivatives of testosterone comprises testosterone active in an amount of from 5% to 30% by weight of the pharmaceutical composition.

2. A pharmaceutical composition according to Claim 1, in which the pharmaceutically acceptable oily vehicle is selected from any one or mixture of a vegetable oil and sucrose acetate isobutyrate (SAIB).

3. A pharmaceutical composition according to Claim 1 or 2, in which the pharmaceutically acceptable oily vehicle is a vegetable oil or mixture of vegetable oils.

4. A pharmaceutical composition according to Claim 1, 2 or 3, in which the pharmaceutically acceptable oily vehicle is comprised of >75% w/w castor oil.

5. A pharmaceutical composition according to any preceding claim, in which the pharmaceutically acceptable oily vehicle is comprised of >75% w/w medium chain triglycerides (MCT).

6. A pharmaceutical composition according to Claim 1 or 2, in which the pharmaceutically acceptable oily vehicle is sucrose acetate isobutyrate (SAIB).

7. A pharmaceutical composition according to any preceding claim, in which the active ester derivative of testosterone or mixture of active ester derivatives of testosterone comprises testosterone active in an amount of from 10% to 30% by weight of the pharmaceutical composition.

8. A pharmaceutical composition according to any preceding claim, which is thixotropic.

9. A pharmaceutical composition according to any preceding claim, which is a solid or wax.

10. A pharmaceutical composition according to any preceding claim, in which the composition is placed in a spray dispenser for administration to a subject in need thereof.

11. A pharmaceutical composition according to any of Claims 1 to 9, in which the pharmaceutical composition is a gel for administration to a subject in need thereof.

12. A pharmaceutical composition according to any preceding claim, in which a single dose of the pharmaceutical composition delivers up to about 100 mg of testosterone per day.

13. A pharmaceutical composition according to any preceding claim, which allows a patient to self-medicate.

14. A pharmaceutical composition according to any preceding claim for use in a method of treatment of an indication from which a subject suffers, in which the pharmaceutical composition allows a patient to achieve in a single daily administration to both nostrils a quantity of testosterone sufficient to treat the indication.

15. A pharmaceutical composition according to any of Claims 1 to 13 for use in testosterone replacement therapy.

16. A pharmaceutical composition for use according to Claim 14 or 15, which comprises an effective mount of an active ester derivative of testosterone for achieving supraphysiological levels of testosterone for use to treat conditions selected from a group consisting of hypogonadism, anxiety, fear, sexual dysfunction, declining sexual drive, libido, testosterone replacement therapy, low testosterone, depression and anemia.